Abstract: An embodiment ionomer for a fuel cell includes a copolymer having no carbon-oxygen bond, wherein the copolymer includes hydrophilic moieties disposed at both ends, wherein each hydrophilic moiety includes a styrene unit and a proton conductive functional group, and a hydrophobic moiety interposed between the hydrophilic moieties, wherein the hydrophobic moiety includes an ethylene-based unit, a butylene-based unit, an isoprene-based unit, or any combination thereof.

Abstract: The present invention relates to a robot including a hydraulic power unit comprising: a body having a hydraulic channel through which a fluid is movable, a hydraulic power unit having a plurality of pumps and discharging a fluid to the hydraulic channel by using rotational force of the plurality of pumps, and a control unit for controlling the rotation of the plurality of pumps, wherein the plurality of pumps comprises: a first pump rotating in a first rotational direction and discharging a fluid to the hydraulic channel by a rotational force in the first rotational direction, and a second pump rotating in a second rotational direction and discharging a fluid to the hydraulic channel by a rotational force in the second rotational direction, wherein the first rotational direction is different from the second rotational direction.

Abstract: The present disclosure relates to a printed circuit board including, a first insulating layer, a first metal layer disposed on the first insulating layer, a bridge disposed on the first metal layer and including a bridge insulating layer and a bridge circuit layer, a second insulating layer disposed on the first insulating layer and covering at least a portion of the bridge, a second metal layer disposed on the second insulating layer, and a connecting via penetrating the bridge and the second insulating layer to connect the first metal layer to the second insulating layer. The connecting via is spaced apart from the bridge circuit layer.

Abstract: A method of operating a memory device includes reading a first page of memory cells containing at least one worn-out memory cell therein using a read voltage, from a first memory block, and reading a second page of memory cells, which extends adjacent to the first page in the first memory block, using the read voltage. An operation is performed to determine a match rate between a position of a column including a “0” bit in the first page with a position of a column including a “0” bit in the second page. Thereafter, the second page is read by adjusting a read pass voltage applied to a word line of another page in the first memory block, when the match rate exceeds a threshold match rate.

Abstract: A display device includes an electronic panel including a first non-folding region, a folding region, and a second non-folding region arranged in a first direction, a support plate disposed under the electronic panel, and a hinge member that defines biaxial rotational axes that are spaced apart from each other in the first direction and that extend in a second direction crossing the first direction. The electronic panel is folded inward or outward about the biaxial rotational axes, and the biaxial rotational axes are defined over or under the support plate depending on a folding direction of the electronic panel.

Abstract: A light emitting diode package includes: a housing; a light emitting diode chip arranged in the housing; a wavelength conversion unit arranged on the light emitting diode chip; a first fluorescent substance distributed inside the wavelength conversion unit and emitting light having a peak wavelength in the cyan wavelength band; and a second fluorescent substance distributed inside the wavelength conversion unit and emitting light having a peak wavelength in the red wavelength band, wherein the peak wavelength of light emitted from the light emitting diode chip is located within a range of 415 nm to 430 nm.

Abstract: The present invention relates to the treatment of dry eye disease and particularly, although not exclusively, to the treatment of dry eye disease with a LINK_TSG6 polypeptide.

Abstract: This invention relates to a method of treating biliary tract cancer by administering to a patient in need thereof, over a period of time, therapeutic agents comprising a MEK inhibitor or a pharmaceutically acceptable salt thereof, and a fluoropyrimidine-containing therapy, to a patient in need thereof.

Abstract: An electronic component (and/or an electronic device comprising the same) according to various embodiments of the present invention comprises: a substrate having a sensing element mounted on one surface thereof; a flexible printed circuit board that is coupled to the other surface of the substrate so as to face the same and extends to a side of the substrate along a first direction; and at least one recess formed on the edge of the other surface of the substrate, wherein the recess is located in an area, on the other surface of the substrate, which faces at least the flexible printed circuit board, and may extend along a second direction intersecting with the first direction. The electronic component and/or the electronic device comprising the same as described above may be diversified according to embodiments.

Abstract: A light emitting diode package includes: a housing; a light emitting diode chip arranged in the housing; a wavelength conversion unit arranged on the light emitting diode chip; a first fluorescent substance distributed inside the wavelength conversion unit and emitting light having a peak wavelength in the cyan wavelength band; and a second fluorescent substance distributed inside the wavelength conversion unit and emitting light having a peak wavelength in the red wavelength band, wherein the peak wavelength of light emitted from the light emitting diode chip is located within a range of 415 nm to 430 nm.

Abstract: A light emitting diode package includes: a housing; a light emitting diode chip arranged in the housing; a wavelength conversion unit arranged on the light emitting diode chip; a first fluorescent substance distributed inside the wavelength conversion unit and emitting light having a peak wavelength in the cyan wavelength band; and a second fluorescent substance distributed inside the wavelength conversion unit and emitting light having a peak wavelength in the red wavelength band, wherein the peak wavelength of light emitted from the light emitting diode chip is located within a range of 415 nm to 430 nm.

Abstract: An electronic component (and/or an electronic device comprising the same) according to various embodiments of the present invention comprises: a substrate having a sensing element mounted on one surface thereof; a flexible printed circuit board that is coupled to the other surface of the substrate so as to face the same and extends to a side of the substrate along a first direction; and at least one recess formed on the edge of the other surface of the substrate, wherein the recess is located in an area, on the other surface of the substrate, which faces at least the flexible printed circuit board, and may extend along a second direction intersecting with the first direction. The electronic component and/or the electronic device comprising the same as described above may be diversified according to embodiments.

Abstract: Pharmaceutically acceptable preparations of extracellular vesicles derived from activated MSCs are provided. These preparations are essentially free of MSCs, and demonstrate anti-inflammatory inhibiting pharmacological activity in vivo. Methods for using the preparations to prevent the onset of autoimmune diseases are presented. The MSC derived extracellular vesicles are provided in pharmaceutically acceptable preparations with a carrier, such as saline, and may be used to inhibit activation of antigen presenting cells. These preparations may also be used to suppress the development of T helper 1 (Th1) and Th17 cells. The disclosed activated MSC-derived extracellular vesicle preparations are essentially free of MSCs and other cells.

Abstract: Improved methods of treatment are provided for patients suffering from cancer. The methods identify whether a tumor will be responsive to treatment with a therapeutic regime that includes anti-Her2 therapeutic agents. A specific Her2 fragment peptide is precisely quantitated by SRM-mass spectrometry directly in tumor cells collected from tumor tissue that was obtained from a cancer patient and compared to a reference level in order to determine if the cancer patient will positively respond to treatment with a therapeutic agent that specifically targets the Her2 protein.

Abstract: Isolated mesenchymal stem cells, which produce mRNA encoding TSG-6 protein or a biologically active fragment, derivative, or analogue thereof in an amount of at least a first preselected amount, or produce mRNA encoding TSG-6 protein or a biologically active fragment, derivative, or analogue thereof in an amount that does not exceed a second preselected amount, as determined by an assay, such as a RT-PCR assay. Isolated mesenchymal stem cells that produce mRNA encoding TSG-6 protein or a biologically active fragment, derivative, or analogue thereof in an amount of at least the first preselected amount are useful in treating diseases, conditions, and disorders associated with inflammation, while isolated mesenchymal stem cells that produce mRNA encoding TSG-6 protein or a biologically active fragment, derivative, or analogue thereof in an amount that does not exceed the second preselected amount are useful in treating bone diseases, conditions, and disorders, including bone injuries.

Abstract: The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.

Abstract: The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.

Abstract: A light emitting diode package includes: a housing; a light emitting diode chip arranged in the housing; a wavelength conversion unit arranged on the light emitting diode chip; a first fluorescent substance distributed inside the wavelength conversion unit and emitting light having a peak wavelength in the cyan wavelength band; and a second fluorescent substance distributed inside the wavelength conversion unit and emitting light having a peak wavelength in the red wavelength band, wherein the peak wavelength of light emitted from the light emitting diode chip is located within a range of 415 nm to 430 nm.

Abstract: The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.

Abstract: The present invention relates to a preparation method of drug-containing sustained release microparticles, the preparation method comprising the steps of: (a) dissolving a biodegradable polymer and a drug in a halogenated alkane solvent to form a drug-containing biodegradable polymer solution; (b) homogeneously mixing the drug-containing biodegradable polymer solution in a continuous phase containing a surfactant to form a dispersed phase; (c) maintaining an emulsion comprising the continuous phase and the dispersed phase at a temperature lower than the boiling point of the halogenated alkane solvent to form microparticles in the continuous phase; (d) primarily drying the microparticles; (e) mixing the primarily dried microparticles with an aqueous alcohol solution, and then maintaining the aqueous alcohol solution at a temperature no less than the boiling point of the halogenated alkane solvent to extract and evaporate the remaining halogenated alkane solvent from the microparticles; and (f) secondarily dryi